Wisecort Tablet contains Deflazacort 6 mg, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It is primarily indicated for the management of various inflammatory and autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, and certain allergic disorders. Deflazacort exerts its therapeutic effects by modulating the immune response and reducing inflammation through inhibition of multiple inflammatory mediators. Compared to other corticosteroids, Deflazacort is associated with a relatively favorable safety profile, demonstrating reduced impact on calcium metabolism and a lower risk of corticosteroid-induced osteoporosis. Wisecort Tablet is also utilized in the treatment of Duchenne muscular dystrophy to improve muscle strength and function. The dosage regimen should be individualized based on the patient’s condition, severity, and response to therapy, with gradual tapering recommended to minimize adrenal insufficiency risk. Common adverse effects may include gastrointestinal discomfort, increased susceptibility to infections, hyperglycemia, hypertension, and mood alterations. Caution is advised in patients with diabetes, hypertension, peptic ulcer disease, and those receiving immunosuppressive therapy. Regular monitoring of clinical status and laboratory parameters is essential during prolonged treatment. Wisecort Tablet should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize potential side effects.